Bronchial challenges in athletes applying to inhale a ß-2 agonist at the 2004 Summer Olympics

S. D. Anderson, M. Sue-Chu, C. P. Perry, C. Gratziou, Pascale Kippelen, D. C. Mckenzie, K. C. Beck, K. D. Fitch

    Research output: Contribution to journalArticle

    69 Citations (Scopus)

    Abstract

    Background: The International Olympic Committee Medical Commission required a medical justification for athletes to inhale a beta(2)-agonist before an event at the Summer Games in Athens in 2004.

    Objective: We sought to establish the percentage of athletes applying to use an inhaled beta(2)-agonist on the basis of the results of objective tests to establish a diagnosis of asthma or exercise-induced bronchoconstriction. We also sought to compare this percentage with the percentage of athletes simply notifying the intention to use a beta(2)-agonist at the previous Summer Games in Sydney in 2000.

    Methods: An analysis was made of tests that measured the change in FEV1 in response to a bronchodilator or in response to a provoking stimulus, such as exercise, eucapnic voluntary hyperpnea, hypertonic saline, or methacholine.

    Results: Ten thousand six hundred fifty-three athletes competed in Athens; 4.2% were approved to use a beta(2)-agonist, and 0.4% were rejected. This approval rate was 26% less than the notifications in 2000 in Sydney (5.7%). Compared with Sydney 2000, there was a significant reduction of submissions and approvals for athletes from the United States, New Zealand, Australia, and Canada and in triathlon and swimming sports.

    Conclusion: The need to provide objective testing has resulted in a reduction in the number of athletes seeking approval to use an inhaled beta(2)-agonist. Objective evidence has provided information for the doctor that is likely to improve the health of the athlete because many athletes appeared to be undertreated at the time of testing.

    Clinical implications: We show that documentation of airway narrowing in athletes, particularly in response to exercise or surrogate stimuli for exercise, aids in the diagnosis and management of asthma by providing evidence of bronchial hyperresponsiveness that will respond to treatment with inhaled corticosteroids and is usually associated with a reduction in respiratory symptoms on exercise.

    Original languageEnglish
    Pages (from-to)767-773
    Number of pages6
    JournalJournal of Allergy and Clinical Immunology
    Volume117
    Issue number4
    DOIs
    Publication statusPublished - Apr 2006

    Keywords

    • athletes
    • asthma
    • beta(2)-agonist
    • bronchial provocation
    • exercise
    • eucapnic hyperpnea
    • methacholine
    • EXERCISE-INDUCED ASTHMA
    • LUNG-FUNCTION TESTS
    • WORKING PARTY STANDARDIZATION
    • EUROPEAN RESPIRATORY SOCIETY
    • AIRWAY INFLAMMATION
    • INDUCED BRONCHOCONSTRICTION
    • OFFICIAL STATEMENT
    • RESPONSIVENESS
    • COMMUNITY
    • HYPERRESPONSIVENESS

    Cite this

    Anderson, S. D., Sue-Chu, M., Perry, C. P., Gratziou, C., Kippelen, P., Mckenzie, D. C., ... Fitch, K. D. (2006). Bronchial challenges in athletes applying to inhale a ß-2 agonist at the 2004 Summer Olympics. Journal of Allergy and Clinical Immunology, 117(4), 767-773. https://doi.org/10.1016/j.jaci.2005.12.1355

    Bronchial challenges in athletes applying to inhale a ß-2 agonist at the 2004 Summer Olympics. / Anderson, S. D.; Sue-Chu, M.; Perry, C. P.; Gratziou, C.; Kippelen, Pascale; Mckenzie, D. C.; Beck, K. C.; Fitch, K. D.

    In: Journal of Allergy and Clinical Immunology, Vol. 117, No. 4, 04.2006, p. 767-773.

    Research output: Contribution to journalArticle

    Anderson, SD, Sue-Chu, M, Perry, CP, Gratziou, C, Kippelen, P, Mckenzie, DC, Beck, KC & Fitch, KD 2006, 'Bronchial challenges in athletes applying to inhale a ß-2 agonist at the 2004 Summer Olympics', Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. 767-773. https://doi.org/10.1016/j.jaci.2005.12.1355
    Anderson, S. D. ; Sue-Chu, M. ; Perry, C. P. ; Gratziou, C. ; Kippelen, Pascale ; Mckenzie, D. C. ; Beck, K. C. ; Fitch, K. D. / Bronchial challenges in athletes applying to inhale a ß-2 agonist at the 2004 Summer Olympics. In: Journal of Allergy and Clinical Immunology. 2006 ; Vol. 117, No. 4. pp. 767-773.
    @article{5e345d4b5e404704a04b1bebdb2c3382,
    title = "Bronchial challenges in athletes applying to inhale a {\ss}-2 agonist at the 2004 Summer Olympics",
    abstract = "Background: The International Olympic Committee Medical Commission required a medical justification for athletes to inhale a beta(2)-agonist before an event at the Summer Games in Athens in 2004.Objective: We sought to establish the percentage of athletes applying to use an inhaled beta(2)-agonist on the basis of the results of objective tests to establish a diagnosis of asthma or exercise-induced bronchoconstriction. We also sought to compare this percentage with the percentage of athletes simply notifying the intention to use a beta(2)-agonist at the previous Summer Games in Sydney in 2000.Methods: An analysis was made of tests that measured the change in FEV1 in response to a bronchodilator or in response to a provoking stimulus, such as exercise, eucapnic voluntary hyperpnea, hypertonic saline, or methacholine.Results: Ten thousand six hundred fifty-three athletes competed in Athens; 4.2{\%} were approved to use a beta(2)-agonist, and 0.4{\%} were rejected. This approval rate was 26{\%} less than the notifications in 2000 in Sydney (5.7{\%}). Compared with Sydney 2000, there was a significant reduction of submissions and approvals for athletes from the United States, New Zealand, Australia, and Canada and in triathlon and swimming sports.Conclusion: The need to provide objective testing has resulted in a reduction in the number of athletes seeking approval to use an inhaled beta(2)-agonist. Objective evidence has provided information for the doctor that is likely to improve the health of the athlete because many athletes appeared to be undertreated at the time of testing.Clinical implications: We show that documentation of airway narrowing in athletes, particularly in response to exercise or surrogate stimuli for exercise, aids in the diagnosis and management of asthma by providing evidence of bronchial hyperresponsiveness that will respond to treatment with inhaled corticosteroids and is usually associated with a reduction in respiratory symptoms on exercise.",
    keywords = "athletes, asthma, beta(2)-agonist, bronchial provocation, exercise, eucapnic hyperpnea, methacholine, EXERCISE-INDUCED ASTHMA, LUNG-FUNCTION TESTS, WORKING PARTY STANDARDIZATION, EUROPEAN RESPIRATORY SOCIETY, AIRWAY INFLAMMATION, INDUCED BRONCHOCONSTRICTION, OFFICIAL STATEMENT, RESPONSIVENESS, COMMUNITY, HYPERRESPONSIVENESS",
    author = "Anderson, {S. D.} and M. Sue-Chu and Perry, {C. P.} and C. Gratziou and Pascale Kippelen and Mckenzie, {D. C.} and Beck, {K. C.} and Fitch, {K. D.}",
    year = "2006",
    month = "4",
    doi = "10.1016/j.jaci.2005.12.1355",
    language = "English",
    volume = "117",
    pages = "767--773",
    journal = "Journal of Allergy and Clinical Immunology",
    issn = "0091-6749",
    publisher = "Mosby/Elsevier,",
    number = "4",

    }

    TY - JOUR

    T1 - Bronchial challenges in athletes applying to inhale a ß-2 agonist at the 2004 Summer Olympics

    AU - Anderson, S. D.

    AU - Sue-Chu, M.

    AU - Perry, C. P.

    AU - Gratziou, C.

    AU - Kippelen, Pascale

    AU - Mckenzie, D. C.

    AU - Beck, K. C.

    AU - Fitch, K. D.

    PY - 2006/4

    Y1 - 2006/4

    N2 - Background: The International Olympic Committee Medical Commission required a medical justification for athletes to inhale a beta(2)-agonist before an event at the Summer Games in Athens in 2004.Objective: We sought to establish the percentage of athletes applying to use an inhaled beta(2)-agonist on the basis of the results of objective tests to establish a diagnosis of asthma or exercise-induced bronchoconstriction. We also sought to compare this percentage with the percentage of athletes simply notifying the intention to use a beta(2)-agonist at the previous Summer Games in Sydney in 2000.Methods: An analysis was made of tests that measured the change in FEV1 in response to a bronchodilator or in response to a provoking stimulus, such as exercise, eucapnic voluntary hyperpnea, hypertonic saline, or methacholine.Results: Ten thousand six hundred fifty-three athletes competed in Athens; 4.2% were approved to use a beta(2)-agonist, and 0.4% were rejected. This approval rate was 26% less than the notifications in 2000 in Sydney (5.7%). Compared with Sydney 2000, there was a significant reduction of submissions and approvals for athletes from the United States, New Zealand, Australia, and Canada and in triathlon and swimming sports.Conclusion: The need to provide objective testing has resulted in a reduction in the number of athletes seeking approval to use an inhaled beta(2)-agonist. Objective evidence has provided information for the doctor that is likely to improve the health of the athlete because many athletes appeared to be undertreated at the time of testing.Clinical implications: We show that documentation of airway narrowing in athletes, particularly in response to exercise or surrogate stimuli for exercise, aids in the diagnosis and management of asthma by providing evidence of bronchial hyperresponsiveness that will respond to treatment with inhaled corticosteroids and is usually associated with a reduction in respiratory symptoms on exercise.

    AB - Background: The International Olympic Committee Medical Commission required a medical justification for athletes to inhale a beta(2)-agonist before an event at the Summer Games in Athens in 2004.Objective: We sought to establish the percentage of athletes applying to use an inhaled beta(2)-agonist on the basis of the results of objective tests to establish a diagnosis of asthma or exercise-induced bronchoconstriction. We also sought to compare this percentage with the percentage of athletes simply notifying the intention to use a beta(2)-agonist at the previous Summer Games in Sydney in 2000.Methods: An analysis was made of tests that measured the change in FEV1 in response to a bronchodilator or in response to a provoking stimulus, such as exercise, eucapnic voluntary hyperpnea, hypertonic saline, or methacholine.Results: Ten thousand six hundred fifty-three athletes competed in Athens; 4.2% were approved to use a beta(2)-agonist, and 0.4% were rejected. This approval rate was 26% less than the notifications in 2000 in Sydney (5.7%). Compared with Sydney 2000, there was a significant reduction of submissions and approvals for athletes from the United States, New Zealand, Australia, and Canada and in triathlon and swimming sports.Conclusion: The need to provide objective testing has resulted in a reduction in the number of athletes seeking approval to use an inhaled beta(2)-agonist. Objective evidence has provided information for the doctor that is likely to improve the health of the athlete because many athletes appeared to be undertreated at the time of testing.Clinical implications: We show that documentation of airway narrowing in athletes, particularly in response to exercise or surrogate stimuli for exercise, aids in the diagnosis and management of asthma by providing evidence of bronchial hyperresponsiveness that will respond to treatment with inhaled corticosteroids and is usually associated with a reduction in respiratory symptoms on exercise.

    KW - athletes

    KW - asthma

    KW - beta(2)-agonist

    KW - bronchial provocation

    KW - exercise

    KW - eucapnic hyperpnea

    KW - methacholine

    KW - EXERCISE-INDUCED ASTHMA

    KW - LUNG-FUNCTION TESTS

    KW - WORKING PARTY STANDARDIZATION

    KW - EUROPEAN RESPIRATORY SOCIETY

    KW - AIRWAY INFLAMMATION

    KW - INDUCED BRONCHOCONSTRICTION

    KW - OFFICIAL STATEMENT

    KW - RESPONSIVENESS

    KW - COMMUNITY

    KW - HYPERRESPONSIVENESS

    U2 - 10.1016/j.jaci.2005.12.1355

    DO - 10.1016/j.jaci.2005.12.1355

    M3 - Article

    VL - 117

    SP - 767

    EP - 773

    JO - Journal of Allergy and Clinical Immunology

    JF - Journal of Allergy and Clinical Immunology

    SN - 0091-6749

    IS - 4

    ER -